Genomictree Inc.
228760
Rangering i aksjer
#19175
Genomictree Inc. is a molecular diagnostics firm that harnesses biomarkers to... Genomictree Inc. is a molecular diagnostics firm that harnesses biomarkers to develop and market advanced detection tools for both oncological conditions and various infectious diseases. Its product line includes EarlyTect C, a screening solution for the early identification of colorectal cancer. For lung cancer, it offers EarlyTect L, which targets epigenetic markers in patients with pulmonary nodules, and for bladder cancer, EarlyTect B, designed to detect specific genetic and epigenetic markers in individuals with hematuria. The company also provides a range of companion diagnostics: AccuraTect-KRAS and AccuraTect-BRAF assist in colorectal cancer management, while AccuraTect-EGFR supports lung cancer treatment. In addition, Genomictree supplies AccuraDTect SARS-CoV-2 RT-qPCR kits for infectious disease testing, and offers its technologies to support various diagnostic test providers. Founded in 2000, the company is based in Daejeon, South Korea.
Aksjekurs
$6.61
Markedsverdi
$162.26M
Endring (1 dag)
1.06%
Endring (1 år)
-50.87%
Land
KR
Handel Genomictree Inc. (228760)
Kategori
Healthcare
Markedsverdi av Genomictree Inc.(228760)
Markedsverdi: $162.26M
Per October 2026 har Genomictree Inc. en markedsverdi på $162.26M. Dette gjør Genomictree Inc. til det 19175th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Genomictree Inc. fra 2017 til 2026
228760 sammenlignet med topp 5 mest populære stocks
